OA12325A - Estrogen agonist/antagonist metabolites. - Google Patents
Estrogen agonist/antagonist metabolites. Download PDFInfo
- Publication number
- OA12325A OA12325A OA1200200305A OA1200200305A OA12325A OA 12325 A OA12325 A OA 12325A OA 1200200305 A OA1200200305 A OA 1200200305A OA 1200200305 A OA1200200305 A OA 1200200305A OA 12325 A OA12325 A OA 12325A
- Authority
- OA
- OAPI
- Prior art keywords
- phenyl
- métabolite
- ethoxy
- pptn
- tetrahydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26719800P | 2000-04-07 | 2000-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA12325A true OA12325A (en) | 2004-04-13 |
Family
ID=23017734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200200305A OA12325A (en) | 2000-04-07 | 2001-03-19 | Estrogen agonist/antagonist metabolites. |
Country Status (38)
Country | Link |
---|---|
US (2) | US6455572B1 (es) |
EP (1) | EP1268453B1 (es) |
JP (1) | JP2004510693A (es) |
KR (1) | KR20020089434A (es) |
CN (1) | CN1209353C (es) |
AP (1) | AP2002002641A0 (es) |
AR (1) | AR035330A1 (es) |
AT (1) | ATE333450T1 (es) |
AU (2) | AU4098501A (es) |
BG (1) | BG107137A (es) |
BR (1) | BR0109838A (es) |
CA (1) | CA2405070A1 (es) |
CR (1) | CR6766A (es) |
CZ (1) | CZ20023223A3 (es) |
DE (1) | DE60121557T2 (es) |
DK (1) | DK1268453T3 (es) |
EA (1) | EA004866B1 (es) |
EE (1) | EE200200580A (es) |
ES (1) | ES2266169T3 (es) |
HK (1) | HK1052511B (es) |
HR (1) | HRP20020802A2 (es) |
HU (1) | HUP0300419A3 (es) |
IL (1) | IL152082A0 (es) |
IS (1) | IS6549A (es) |
MA (1) | MA26890A1 (es) |
MX (1) | MXPA02009940A (es) |
NO (1) | NO20024767L (es) |
OA (1) | OA12325A (es) |
PA (1) | PA8514901A1 (es) |
PE (1) | PE20011183A1 (es) |
PL (1) | PL358593A1 (es) |
PT (1) | PT1268453E (es) |
SK (1) | SK14092002A3 (es) |
TN (1) | TNSN01052A1 (es) |
TR (1) | TR200202310T2 (es) |
UY (1) | UY26656A1 (es) |
WO (1) | WO2001077093A1 (es) |
ZA (1) | ZA200207995B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US7001926B2 (en) | 2000-03-10 | 2006-02-21 | Oxigene, Inc. | Tubulin binding agents and corresponding prodrug constructs |
US7091240B2 (en) | 2000-03-10 | 2006-08-15 | Oxigene, Inc. | Tubulin binding ligands and corresponding prodrug constructs |
CZ289261B6 (cs) * | 2000-07-11 | 2001-12-12 | Léčiva, A.S. | Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby |
EP1192945A3 (en) * | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
AU781168B2 (en) * | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
EP1470137B1 (en) * | 2002-01-18 | 2009-09-02 | Merck & Co., Inc. | Edg receptor agonists |
WO2003076930A1 (en) * | 2002-03-14 | 2003-09-18 | Warner-Lambert Company Llc | Method for characterizing metabolites using hydrogen/deuterium exchange |
EP1658036A2 (en) * | 2003-08-26 | 2006-05-24 | Board of Regents of the University of Texas System | Estrogen receptor modulators and uses thereof |
US7456214B2 (en) | 2004-05-03 | 2008-11-25 | Baylor University | Chromene-containing compounds with anti-tubulin and vascular targeting activity |
BRPI0514273A (pt) | 2004-08-13 | 2008-06-10 | Wyeth Corp | composto, kit para monitorar terapia com tanaproget, método para detectar metabólitos de tanaproget, anticorpo, composição, kit para detectar metabólicos de tanaproget, e, uso de um derivado de glucuronìdeo de tanaproget ou um seu sal farmaceuticamente aceitável |
AU2012200714B2 (en) * | 2004-08-13 | 2014-04-17 | Wyeth Llc | Tanaproget derivatives, metabolites, and uses thereof |
CA2611035C (en) * | 2005-06-22 | 2010-09-14 | Pfizer Products Inc. | Stereoselective hydrogenation process for preparing cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2-methoxy-5,6,7,8-tetrahydronaphthalene hydrochloride |
US7902147B2 (en) * | 2007-11-05 | 2011-03-08 | Duke University | Chronic lymphocytic leukemia prognosis and treatment |
TW201043595A (en) * | 2009-03-13 | 2010-12-16 | Organon Nv | Tetrahydronaphthalen-2-ol derivatives |
WO2016097071A1 (en) * | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3522319A (en) * | 1964-01-23 | 1970-07-28 | Ciba Geigy Corp | Phenol substituted tetrahydronaphthalenes useful as estrogenics |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
UA51676C2 (uk) | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
TW442286B (en) | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
-
2001
- 2001-03-19 CZ CZ20023223A patent/CZ20023223A3/cs unknown
- 2001-03-19 KR KR1020027013379A patent/KR20020089434A/ko active Search and Examination
- 2001-03-19 EE EEP200200580A patent/EE200200580A/xx unknown
- 2001-03-19 AU AU4098501A patent/AU4098501A/xx active Pending
- 2001-03-19 PT PT01912069T patent/PT1268453E/pt unknown
- 2001-03-19 HU HU0300419A patent/HUP0300419A3/hu unknown
- 2001-03-19 JP JP2001575567A patent/JP2004510693A/ja not_active Withdrawn
- 2001-03-19 ES ES01912069T patent/ES2266169T3/es not_active Expired - Lifetime
- 2001-03-19 AU AU2001240985A patent/AU2001240985B2/en not_active Ceased
- 2001-03-19 OA OA1200200305A patent/OA12325A/en unknown
- 2001-03-19 PL PL01358593A patent/PL358593A1/xx not_active Application Discontinuation
- 2001-03-19 EA EA200200949A patent/EA004866B1/ru not_active IP Right Cessation
- 2001-03-19 DK DK01912069T patent/DK1268453T3/da active
- 2001-03-19 CN CNB018077935A patent/CN1209353C/zh not_active Expired - Fee Related
- 2001-03-19 EP EP01912069A patent/EP1268453B1/en not_active Expired - Lifetime
- 2001-03-19 AT AT01912069T patent/ATE333450T1/de not_active IP Right Cessation
- 2001-03-19 MX MXPA02009940A patent/MXPA02009940A/es active IP Right Grant
- 2001-03-19 IL IL15208201A patent/IL152082A0/xx unknown
- 2001-03-19 CA CA002405070A patent/CA2405070A1/en not_active Abandoned
- 2001-03-19 TR TR2002/02310T patent/TR200202310T2/xx unknown
- 2001-03-19 DE DE60121557T patent/DE60121557T2/de not_active Expired - Fee Related
- 2001-03-19 BR BR0109838-1A patent/BR0109838A/pt not_active IP Right Cessation
- 2001-03-19 SK SK1409-2002A patent/SK14092002A3/sk unknown
- 2001-03-19 AP APAP/P/2002/002641A patent/AP2002002641A0/en unknown
- 2001-03-19 WO PCT/IB2001/000427 patent/WO2001077093A1/en active IP Right Grant
- 2001-04-04 US US09/825,980 patent/US6455572B1/en not_active Ceased
- 2001-04-05 PE PE2001000320A patent/PE20011183A1/es not_active Application Discontinuation
- 2001-04-05 UY UY26656A patent/UY26656A1/es not_active Application Discontinuation
- 2001-04-05 AR ARP010101626A patent/AR035330A1/es unknown
- 2001-04-06 TN TNTNSN01052A patent/TNSN01052A1/fr unknown
- 2001-04-09 PA PA20018514901A patent/PA8514901A1/es unknown
-
2002
- 2002-09-17 IS IS6549A patent/IS6549A/is unknown
- 2002-09-23 BG BG107137A patent/BG107137A/bg unknown
- 2002-10-02 MA MA26847A patent/MA26890A1/fr unknown
- 2002-10-02 CR CR6766A patent/CR6766A/es not_active Application Discontinuation
- 2002-10-03 NO NO20024767A patent/NO20024767L/no not_active Application Discontinuation
- 2002-10-04 ZA ZA200207995A patent/ZA200207995B/en unknown
- 2002-10-07 HR HR20020802A patent/HRP20020802A2/hr not_active Application Discontinuation
-
2003
- 2003-05-30 US US10/448,751 patent/USRE39419E1/en not_active Expired - Fee Related
- 2003-07-08 HK HK03104866.0A patent/HK1052511B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA12325A (en) | Estrogen agonist/antagonist metabolites. | |
AU2001240985A1 (en) | Estrogen agonist/antagonist metabolites | |
JP7290638B2 (ja) | Wee1阻害剤としての大環状化合物及びその使用 | |
JP2020531481A (ja) | エーテル化合物およびその使用 | |
JP2004510693A5 (es) | ||
JP2008508198A (ja) | MTPおよびApoBの新規なアザインドール阻害剤 | |
JP2011528037A (ja) | 金属キレート化剤としてのデスアザデスフェリチオシンポリエーテル類似体の新規の塩及び多形体 | |
EP4289841A1 (en) | Benzo seven-membered ring bifunctional compound and application thereof | |
WO2013112323A1 (en) | Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors | |
JP7237010B2 (ja) | Hdac6選択的阻害剤およびその製造方法と使用 | |
KR20220161368A (ko) | 물의 존재 하에 메틸화에 의한 mcl-1 저해 화합물의 제조 | |
NZ521291A (en) | Estrogen agonist/antagonist metabolites | |
CN111393500B (zh) | 具有共轭二烯结构c环的齐墩果酸衍生物及其制备方法和应用 | |
HUT66944A (en) | Process for preparation of propylamine derivatives and pharmaceuticals containing them | |
US4904654A (en) | 7-chloro-5,6-dihydro-3-(5-(2-hydroxy-isopropyl)-1,2,4-oxadiazol-3-yl)-5-methyl-6-oxo-4H-imidazo[1,5a][1,4]benzodiazepine | |
JP2010511646A (ja) | 3,4−ジアミノピリジン誘導体 | |
EP2460803B1 (en) | Method for producing thiabenzoazulene propionic acid derivative | |
EP0110484B1 (en) | Derivatives of aminopyridinecarboxylic acids, methods for their preparation and pharmaceutical compositions containing them | |
US5952336A (en) | Hexahydroindenopyridine compounds having antispermatogenic activity | |
WO2019120198A1 (zh) | 一类喹啉衍生物 | |
JP2000506156A (ja) | エンドセリン転化酵素の阻害剤としてのレトロアミド結合を含有する新規の硫黄誘導体 | |
WO2015027058A2 (en) | Cyclolkyl amine compounds | |
CN116554186A (zh) | 螺吡唑酮化合物、其用途、磷酸二酯酶抑制剂及炎性肺损伤和/或肺纤维化的治疗药物 | |
CN118027003A (zh) | 一种protac化合物及其制备方法和作为雌激素受体降解剂的用途 | |
KR100254807B1 (ko) | Acat 억제활성을 갖는 옥심 구조의 신규화합물,그의 제조방법 및 그를 포함하는 조성물 |